

Hani M Babiker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6878092/publications.pdf>

Version: 2024-02-01

60
papers

1,090
citations

566801

15
h-index

454577

30
g-index

62
all docs

62
docs citations

62
times ranked

1986
citing authors

#	ARTICLE	IF	CITATIONS
1	A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. <i>Investigational New Drugs</i> , 2022, 40, 134-141.	1.2	21
2	A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma. <i>Investigational New Drugs</i> , 2022, 40, 81-90.	1.2	3
3	FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3797-3805.	1.1	4
4	Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1-13.	1.9	8
5	Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. <i>JCO Precision Oncology</i> , 2022, , .	1.5	11
6	Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Oncologist</i> , 2021, 26, e1508-e1513.	1.9	16
7	Using Advanced Molecular Profiling to Identify the Origin of and Tailor Treatment for an Intracranial Mass of Unknown Primary. <i>JCO Precision Oncology</i> , 2021, 5, 981-987.	1.5	0
8	Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1047-1056.	1.9	4
9	Exceptional response to cyclophosphamide and dexamethasone in a patient with metastatic castrate-resistant prostate cancer and RB1 mutation. <i>Anti-Cancer Drugs</i> , 2021, 32, 337-343.	0.7	2
10	A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS. <i>Blood</i> , 2021, 138, 3411-3411.	0.6	6
11	Tumor-Treating Fields: A fourth modality in cancer treatment, new practice updates. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103535.	2.0	10
12	Locally Advanced Rectal Cancer Evaluation by Magnetic Resonance Imaging after Neoadjuvant Therapy on Decision Making: Cancer Center Experience and Literature Review. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 254-259.	0.6	2
13	Implementation of a Low-Cost Quality Improvement Intervention Increases Adherence to Cancer Screening Guidelines and Reduces Healthcare Costs at a University Medical Center. <i>Journal of Cancer Education</i> , 2020, 35, 930-936.	0.6	0
14	Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer. <i>JAMA Oncology</i> , 2020, 6, 125.	3.4	53
15	Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. , 2020, 8, e001065.		70
16	Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institution. <i>Annals of Pancreatic Cancer</i> , 2020, 3, 2-2.	1.2	1
17	Rare Tumor-Normal Matched Whole Exome Sequencing Identifies Novel Genomic Pathogenic Germline and Somatic Aberrations. <i>Cancers</i> , 2020, 12, 1618.	1.7	2
18	A Comparative Analysis of Tumors and Plasma Circulating Tumor DNA in 145 Advanced Cancer Patients Annotated by 3 Core Cellular Processes. <i>Cancers</i> , 2020, 12, 701.	1.7	5

#	ARTICLE	IF	CITATIONS
19	Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 621-626.	1.1	9
20	Exposure to proton pump inhibitors and risk of pancreatic cancer: a meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 327-334.	1.0	13
21	Retrospective Real-World Analysis of the Primary Safety Outcomes in Venous Thromboembolism of High-Risk Major Bleeding Cancer Patients Receiving Therapeutic Anticoagulation. <i>Blood</i> , 2020, 136, 15-16.	0.6	1
22	A Multidisciplinary Evaluation of Barriers to Enrolling Cancer Patients into Early Phase Clinical Trials: Challenges and Patient-centric Recommendations. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 675-686.	1.9	2
23	A Rare Cause of Thrombotic Thrombocytopenia Purpura- (TTP-) Like Syndrome, Vitamin B12 Deficiency: Interpretation of Significant Pathological Findings. <i>Case Reports in Hematology</i> , 2019, 2019, 1-5.	0.3	10
24	Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 16-25.	2.0	28
25	PD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath Tumor. <i>Cancer Immunology Research</i> , 2019, 7, 1396-1400.	1.6	16
26	Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 583-592.	1.9	17
27	The association of <i>BRCA1</i> and <i>BRCA2</i> mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. <i>Prostate</i> , 2019, 79, 880-895.	1.2	100
28	Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC). <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 161-177.	1.9	62
29	E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases. <i>Investigational New Drugs</i> , 2019, 37, 636-645.	1.2	22
30	Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP): Protocol for a Feasibility and Exploratory Efficacy Study in Men on Androgen Deprivation Therapy. <i>JMIR Research Protocols</i> , 2019, 8, e12579.	0.5	5
31	Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 866-876.	0.8	13
32	Ublituximab for the treatment of CD20 positive B-cell malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 407-412.	1.9	38
33	Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 186-200.	2.0	80
34	Tumor-Treating Fields: A Fourth Modality in Cancer Treatment. <i>Clinical Cancer Research</i> , 2018, 24, 266-275.	3.2	241
35	Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting. <i>Drugs - Real World Outcomes</i> , 2018, 5, 149-159.	0.7	33
36	Oral Capecitabine Achieves Response in Metastatic Eccrine Carcinoma. <i>Case Reports in Oncological Medicine</i> , 2018, 2018, 1-5.	0.2	5

#	ARTICLE	IF	CITATIONS
37	Exploring the role of oncolytic viruses in hepatobiliary cancers. <i>Immunotherapy</i> , 2018, 10, 971-986.	1.0	9
38	RXÃ, 3117: Activity of an oral antimetabolite nucleoside in subjects with pancreatic cancer. Preliminary results of stage II of the phase Ia/IIb study. <i>Journal of Clinical Oncology</i> , 2018, 36, 396-396.	0.8	1
39	OA17.01 Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD-L1 Expression in the US. <i>Journal of Thoracic Oncology</i> , 2017, 12, S308.	0.5	1
40	MA14.11 An Estimate of the Economic Impact of Immunotherapy Relative to PD-L1 Expression in Brazil - An Update with Brazilian Costs. <i>Journal of Thoracic Oncology</i> , 2017, 12, S427.	0.5	1
41	Survival Impact of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome Positive (Ph+) de novo Acute Myeloid Leukemia (AML). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S296-S297.	0.2	1
42	Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1063-1072.	1.9	8
43	Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma. <i>Anti-Cancer Drugs</i> , 2017, 28, 127-132.	0.7	4
44	Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. <i>Oncolytic Virotherapy</i> , 2017, Volume 6, 11-18.	6.0	32
45	A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 341-341.	0.8	16
46	P2.45: An Estimate of the Economic Impact of Treatment of NSCLC With Immunotherapy Relative to PD-L1 Expression in Brazil. <i>Journal of Thoracic Oncology</i> , 2016, 11, S246.	0.5	1
47	O.03: Cost Effectiveness of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Relative to PD-L1 Expression. <i>Journal of Thoracic Oncology</i> , 2016, 11, S169-S170.	0.5	7
48	Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas. <i>Cancer Investigation</i> , 2016, 34, 57-63.	0.6	0
49	Prostate Cancer-Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-6.	0.2	8
50	A Multicenter, Open-Label, Phase 1 Study Evaluating the Safety and Tolerability of Pegaspargase in Combination with Gemcitabine in Advanced Metastatic Solid Tumors and Lymphoma. <i>Cancer Investigation</i> , 2015, 33, 172-179.	0.6	4
51	Oxaliplatin-induced neuropathy: a tale of two electrolytes. <i>Supportive Care in Cancer</i> , 2015, 23, 1483-1485.	1.0	1
52	Almost Bleeding to Death: The Conundrum of Acquired Megakaryocytic Thrombocytopenia. <i>Case Reports in Hematology</i> , 2014, 2014, 1-5.	0.3	13
53	The great masquerader of malignancy: chronic intestinal pseudo-obstruction. <i>Biomarker Research</i> , 2014, 2, 23.	2.8	17
54	Neuroblastoma of the elderly, an oncologist's nightmare: case presentation, literature review and SEER database analysis. <i>Experimental Hematology and Oncology</i> , 2014, 3, 20.	2.0	29

#	ARTICLE	IF	CITATIONS
55	Basophilic blast phase of chronic myelogenous leukemia. Blood, 2014, 124, 2464-2464.	0.6	2
56	Phase I study of concomitant pemetrexed and cisplatin plus radiation in patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) carcinomas.. Journal of Clinical Oncology, 2014, 32, 145-145.	0.8	0
57	Heart of Lymphoma: Primary Mediastinal Large B-Cell Lymphoma with Endomyocardial Involvement. Case Reports in Oncological Medicine, 2013, 2013, 1-4.	0.2	6
58	Acute Systemic Viral Infection Masquerading as an Infiltrating Lymphoma in an Elderly Patient: A Case Report and Review of the Literature. Case Reports in Medicine, 2013, 2013, 1-5.	0.3	1
59	The Impact of Concomitant Medication Use on Patient Eligibility for Phase I Cancer Clinical Trials. Journal of Cancer, 2012, 3, 345-353.	1.2	15
60	Granulomatous Cholangitis as a Complication of Intravesical BCG Administration for Bladder Cancer. Bjui, 0, , .	0.0	0